Avecho Biotechnology CEO optimistic about phase III insomnia CBD trial

News Direct

Tue, Apr 4, 2023, 10:50 AM

In this article:

Melbourne, Victoria --News Direct-- Avecho Biotechnology Ltd

Avecho Biotechnology Limited (ASX:AVE) CEO Dr Paul Gavin speaks with Proactive after announcing that the company is looking to raise approximately $11 million. Proceeds from the raise will be used to fund a pivotal Phase 3 clinical trial designed to test the company’s proprietary CBD soft-gel capsule for the treatment of insomnia.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

jonathan@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/avecho-biotechnology-ceo-optimistic-about-phase-iii-insomnia-cbd-trial-518056465

CVS tumbles as Aetna faces soaring medical costs and Medicare Advantage hit
CVS echoed rivals in forecasting persistent increases in payouts tied to a surge in post-Covid medical care.
TheStreet•1h ago
Bitcoin Plunges. Here’s Why and How Far Prices Could Fall.
Bitcoin sells off alongside stocks amid wider market jitters. But now the technical backdrop for cryptos is even weaker.
Barrons.com•2h ago
The Secret to Passive Income Is Hiding in This Unstoppable Dividend Stock
This is one of the most reliable cash-generating companies on the stock market.
Motley Fool•2h ago
Tesla lays off executives, cuts Supercharger division
Tesla fired two key executives and trimmed hundreds of staff, gutting its Supercharger program, a leaked email shows.
Autoblog•23h ago
Artificial Intelligence (AI) Isn't Going Anywhere. Here Are 3 Stocks to Buy and Hold for Decades.
These companies are behind the creation and power of AI models that are changing our world.
Motley Fool•3h ago
CVS Health chops 2024 forecast as cost struggles with Medicare Advantage persist
CVS Health missed first-quarter expectations and chopped its 2024 outlook more than a dollar below Wall Street’s forecast. Shares of the health care giant plunged Wednesday morning after the company said it was still struggling with rising costs from care use in its Medicare Advantage business. Company leaders told analysts they were still dealing with rising use from outpatient care and in supplemental benefits.
Associated Press Finance•2h ago
Pfizer Jumps After Raising Its Outlook On The Heels Of A Big Quarterly Beat
Pfizer beat earnings views Wednesday and reported better-than-projected sales. The company raised its profit guide and Pfizer stock jumped.
Investor's Business Daily•1h ago
Dow Jones Falls Ahead Of Fed Decision, Powell Remarks; AMD, Super Micro Dive On Earnings
Stock Market Today: The Dow Jones dropped Wednesday ahead of the Fed decision and Powell's comments. AMD and Super Micro dived on earnings.
Investor's Business Daily•14m ago
This 7.6%-Yielding Dividend Stock Continues to Demonstrate Why It's a Premier Passive Income Investment
Enterprise Products Partners continues to produce plenty of cash to cover its big-time distribution and expansion plan.
Motley Fool•32m ago
Like Realty Income? This Competitor Has an Even Better Dividend Track Record
Realty Income is the leader in the net lease REIT industry, but there's an important area where it is not No. 1.
Motley Fool•5h ago

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Avecho Biotechnology CEO optimistic about phase III insomnia CBD trial

Contact Details

Recommended Stories

CVS tumbles as Aetna faces soaring medical costs and Medicare Advantage hit

Bitcoin Plunges. Here’s Why and How Far Prices Could Fall.

The Secret to Passive Income Is Hiding in This Unstoppable Dividend Stock

Tesla lays off executives, cuts Supercharger division

Artificial Intelligence (AI) Isn't Going Anywhere. Here Are 3 Stocks to Buy and Hold for Decades.

CVS Health chops 2024 forecast as cost struggles with Medicare Advantage persist

Pfizer Jumps After Raising Its Outlook On The Heels Of A Big Quarterly Beat

Dow Jones Falls Ahead Of Fed Decision, Powell Remarks; AMD, Super Micro Dive On Earnings

This 7.6%-Yielding Dividend Stock Continues to Demonstrate Why It's a Premier Passive Income Investment

Like Realty Income? This Competitor Has an Even Better Dividend Track Record